109 related articles for article (PubMed ID: 15360003)
1. Evaluation of temozolomide in patients with myelodysplastic syndrome.
Seiter K; Liu D; Siddiqui AD; Lerner R; Nelson J; Ahmed T
Leuk Lymphoma; 2004 Jun; 45(6):1209-14. PubMed ID: 15360003
[TBL] [Abstract][Full Text] [Related]
2. [Temozolomide, an oral chemotherapeutic agent with potential severe toxicity].
Soetekouw PM; Gijtenbeek JM; van der Maazen RW; Kappelle AC; van Herpen CM
Ned Tijdschr Geneeskd; 2007 Jan; 151(4):253-7. PubMed ID: 17323884
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of temozolomide in relapsed/refractory acute leukemia.
Seiter K; Liu D; Loughran T; Siddiqui A; Baskind P; Ahmed T
J Clin Oncol; 2002 Aug; 20(15):3249-53. PubMed ID: 12149298
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Brandwein JM; Kassis J; Leber B; Hogge D; Howson-Jan K; Minden MD; Galarneau A; Pouliot JF
Br J Haematol; 2014 Dec; 167(5):664-70. PubMed ID: 25160658
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Dufour C; Da Costa L; Auger N; Jullien M; Bhangoo R; Grill J
J Pediatr Hematol Oncol; 2008 Nov; 30(11):857-9. PubMed ID: 18989164
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Rashidi A; Sorscher SM
Leuk Lymphoma; 2015; 56(8):2468-9. PubMed ID: 25530344
[No Abstract] [Full Text] [Related]
8. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Rudek MA; Donehower RC; Statkevich P; Batra VK; Cutler DL; Baker SD
Pharmacotherapy; 2004 Jan; 24(1):16-25. PubMed ID: 14740784
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
10. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Harris MT; Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
Nicholson HS; Krailo M; Ames MM; Seibel NL; Reid JM; Liu-Mares W; Vezina LG; Ettinger AG; Reaman GH
J Clin Oncol; 1998 Sep; 16(9):3037-43. PubMed ID: 9738573
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
14. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Singhal N; Selva-Nayagam S; Brown MP
J Neurooncol; 2007 Nov; 85(2):229-30. PubMed ID: 17530175
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Su YW; Chang MC; Chiang MF; Hsieh RK
J Neurooncol; 2005 Feb; 71(3):315-8. PubMed ID: 15735923
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Bedikian AY; Papadopoulos N; Plager C; Eton O; Ring S
Melanoma Res; 2003 Jun; 13(3):303-6. PubMed ID: 12777987
[TBL] [Abstract][Full Text] [Related]
18. The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Newlands ES; O'Reilly SM; Glaser MG; Bower M; Evans H; Brock C; Brampton MH; Colquhoun I; Lewis P; Rice-Edwards JM; Illingworth RD; Richards PG
Eur J Cancer; 1996 Dec; 32A(13):2236-41. PubMed ID: 9038604
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Schold SC; Kuhn JG; Chang SM; Bosik ME; Robins HI; Mehta MP; Spence AM; Fulton D; Fink KL; Prados MD
Neuro Oncol; 2000 Jan; 2(1):34-9. PubMed ID: 11302252
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
